Last Updated : May 2, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort ascending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Eylea HD | aflibercept 8mg/0.07mL | diabetic macular edema | Active | |||
| Eylea | Aflibercept | Macular edema, branch retinal vein occlusion | Reimburse with clinical criteria and/or conditions | Complete | ||
| Eylea | Aflibercept | Macular edema, diabetic | List with clinical criteria and/or conditions | Complete | ||
| Eylea | Aflibercept | Macular edema, central retinal vein occlusion | List with clinical criteria and/or conditions | Complete | ||
| Eylea | Aflibercept | Macular degeneration, age-related | List with criteria/condition | Complete | ||
| Exjade | Deferasirox | Iron overload | List with clinical criteria and/or conditions | Complete | ||
| Exelon Patch | Rivastigmine | Dementia (Alzheimer's type) | Do not list | Complete | ||
| Evrysdi | risdiplam | Spinal muscular atrophy | Reimburse with clinical criteria and/or conditions | Complete | ||
| Evra | Norgelestromin/ethinyl estradiol | Contraceptive, patch | Do not list | Complete | ||
| Evkeeza | evinacumab | Homozygous familial hypercholesterolemia (HoFH) | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 2, 2024